资料显示，东华软件股份公司位于北京市海淀区紫金数码园3号楼16层，成立日期2001年1月20日，上市 日期2006年8月23日，公司主营业务涉及主要从事行业应用软件开发、计算机信息系统集成及相关服务 业务。主营业务收入构成为：系统集成收入68.15%，技术服务收入17.71%，软件收入14.09%，其他(补 充)0.05%。 2月27日，东华软件盘中上涨2.21%，截至10:44，报9.70元/股，成交3.69亿元，换手率1.32%，总市值 310.93亿元。 资金流向方面，主力资金净流入3258.25万元，特大单买入6388.42万元，占比17.30%，卖出3334.16万 元，占比9.03%；大单买入8353.32万元，占比22.62%，卖出8149.33万元，占比22.07%。 东华软件今年以来股价涨6.01%，近5个交易日跌0.41%，近20日跌2.90%，近60日跌8.32%。 东华软件所属申万行业为：计算机-IT服务Ⅱ-IT服务Ⅲ。所属概念板块包括：医疗信息化、智慧医疗、 国产软件、数字经济、华为算力等。 截至9月30日，东华软件股东户数31.52万，较上期减少2.68%；人均流通股9226股，较 ...

2月3日，2026年中央一号文件《中共中央国务院关于锚定农业农村现代化扎实推进乡村全面振兴的意见》正式发布，对农村卫生健康体系建设、基层医疗服 务能力提升以及紧密型县域医共体发展提出了更加明确的方向。在政策持续推动基层医疗高质量发展的背景下，如何通过专业化与数字化手段提升县域医疗 服务能力，成为行业关注的重点。作为第三方医检行业领军企业， 金域医学 围绕集约化共享、专业化服务与数智化升级，持续探索适配县域医疗发展的整 体解决路径，为紧密型医共体建设提供系统性支撑。 整合区域信息平台，实现医疗数据互联互通 | | | 在赋能县域医疗的数智化转型方面，金域医学构建了"五位一体"的数智化方案。该方案以县域检验中心与病理诊断中心两大共享平台为基石，深度融合了供 应链、实验室与质量管理等系统，并针对具体临床场景开发部署了系列智能应用。通过这一立体化架构，实现了区域医疗资源的数字化高效协同与智能化精 细运营。方案向上能够无缝对接政府卫生监管与决策系统，赋能区域智慧化监管与疾病主动防控；向下则致力于构建覆盖居民全生命周期的健康管理服务， 提升医疗系统的运行效率与服务品质。 打造示范应用模式，探索县域医疗发展新路径 依托覆盖 ...

后续，凯迪网络将持续深耕智慧医疗赛道，同时拓展多领域数字化解决方案布局。 免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。 来源：观点地产网 观点网讯：2月24日，据润华物业官微消息，山东凯迪网络信息技术有限公司成功中标山东第一医科大 学省立医院智慧后勤升级项目与泰安市中心医院物流一体化管理软件系统项目。 据了解，凯迪网络为润华物业智慧化战略的重要支撑，拥有40余项软件著作权及自主知识产权。此次中 标是其"物业后勤一体化"服务新模式的实质性进展，公司针对两家医院的不同需求量身定制方案，凭借 专业技术实力在竞争者中脱颖而出。 ...

麒麟信安云通过按需调配计算资源，为医护人员打造稳定流畅的操作环境，轻松应对各类医疗软件运行 及复杂数据调取处理需求，彻底解决系统卡顿问题，让医护人员专注于诊疗工作、提升服务质量。此次 麒麟信安云的落地应用，不仅重构了医院信息系统平台，更实现了运维管理模式的升级，助力该院加速 智慧医疗转型，推动医疗事业迈向高质量发展新阶段。 在满足终端集中管理的同时，麒麟信安云精准适配各科室专业化需求。肺结核科、呼吸内科借助云桌面 流畅运行影像系统，为医生查看肺部影像、精准诊断提供支撑；门诊护士站通过云桌面承载电子病历、 移动护理及HIS系统，方便护士快速调取病历、查看患者体征与医嘱，提升查房与病情管理效率；妇科 门诊依托云桌面驱动叫号器系统，规范诊疗秩序；口腔科则通过云桌面支持Planmeca Romexis系统，顺 畅完成口腔造影与可视化图像分析。 长沙市某三级甲等综合医院日均住院患者超2300人次、门急诊量达5000余人次，此前传统PC管理模式 下，运维人力紧张、业务响应滞后等问题，严重制约医院信息化发展。依托麒麟信安云技术，该院在数 据中心搭建云桌面服务平台，整合桌面资源池、集中托管医护终端，实现医疗信息系统全面云化升 ...

Performance Overview - The company has released a profit forecast for 2025, expecting a net profit attributable to shareholders to increase by 1660.56% to between 1 billion and 1.5 billion yuan, primarily due to non-recurring gains from the reduction of shares in Fengzhushou (301382) from June to December 2025 [1] - Complete performance data will be available in the upcoming 2025 annual report [1] Stock Performance - On February 5, 2026, the company's stock price hit the daily limit increase of 20%, closing at 14.52 yuan, with a total market capitalization of 9.683 billion yuan [2] - The trading volume on that day was significant, with a turnover rate of 31.49%, indicating intense market speculation driven by the profit forecast and themes related to smart cities and smart healthcare [2] Company Strategy - The company plans to continue focusing on its core businesses in smart cities and smart healthcare while optimizing its asset structure [3] - Despite the optimistic outlook, the company reported a net profit loss excluding non-recurring items for the first three quarters of 2025, highlighting the need to monitor improvements in core business profitability [3]

Core Viewpoint - The company focuses on the smart healthcare sector, aiming for high-quality development through product iteration, market expansion, cost optimization, and resource integration [2] Group 1: Business Strategy - The company is enhancing its profitability by improving its product offerings in AI medical record quality control, emergency critical care, and closing data loops for perioperative care [2] - The company supports intelligent review of medical insurance DRG/DIP and intelligent triage and guidance as part of its product strategy [2] Group 2: Market Focus - The company plans to strengthen regional market collaboration to improve profitability as a core objective [2] - The company commits to regularly disclosing significant business progress to protect the rights of all shareholders [2]

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is focusing on enhancing its strategic partnerships and technological advancements in the healthcare sector, particularly through AI applications and e-commerce platforms [2][3]. Group 1: Company Developments - On October 23, 2025, the company established a strategic partnership with iFlytek Medical to enhance professional service efficiency in pharmacies and address user health needs through the launch of the "Pharmacy AI Health Assistant" [2]. - The company is actively investing in information technology to transition from information-based to intelligent integration, exploring suitable business scenarios for AI applications, which have improved service efficiency and customer experience [2]. - As of September 30, 2025, the company reported a revenue of 3.892 billion yuan, a year-on-year increase of 19.06%, and a net profit attributable to shareholders of 157 million yuan, reflecting a growth of 45.21% [8]. Group 2: Shareholder and Market Information - As of September 30, 2025, the company had 20,100 shareholders, a decrease of 22.86% from the previous period, with an average of 7,422 circulating shares per person, an increase of 29.64% [8]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company's shares, and the company collaborates with various Alibaba platforms, including Alipay and Tmall [3]. - The company has diversified its e-commerce presence, expanding its operations on major platforms such as JD.com, Pinduoduo, and Meituan, achieving significant growth during the reporting period [2].

Core Viewpoint - The company, Fulei New Materials (605488), has indicated that its flexible sensor technology can be applied in various fields such as humanoid robots, industrial inspection, wearable devices, and smart healthcare, with tailored product solutions based on specific customer needs [1] Group 1 - The flexible sensor technology is currently a small portion of the company's overall revenue [1]

Core Viewpoint - Baoji City is enhancing its healthcare services by focusing on home-based medical care, simplifying processes, and improving access to quality medical resources for its residents, particularly vulnerable groups such as the elderly and women [2][3][8] Group 1: Home-Based Medical Services - The community health service center in Jinhe Shangju is providing home visits to residents, particularly targeting the elderly, to ensure they receive necessary medical attention [1][2] - Baoji has implemented a "daily follow-up + on-demand home visit" service model, creating a "health defense line" at residents' doorsteps [2] Group 2: Simplification of Medical Processes - The establishment of a medical testing mutual recognition platform allows 40 medical institutions to share 232 types of test results, benefiting 83,600 patients and saving them 4.46 million yuan [3] - By 2025, Baoji aims to refund 52.41 million yuan in pre-paid outpatient fees, impacting 1.1758 million patients, while also implementing measures to reduce waiting times and improve patient satisfaction [3] Group 3: Quality Medical Resources - Baoji has built 140 standardized traditional Chinese medicine (TCM) clinics, ensuring TCM services are accessible at the community level [5][6] - The city is expanding blood dialysis services to all counties, with 286,000 dialysis sessions planned for 2025, significantly reducing the burden on patients [6] Group 4: Mental Health and Targeted Health Policies - Baoji is integrating mental health services into its healthcare system, with a dedicated psychological assistance hotline and clinics to support residents [7] - The city has introduced policies to support families with multiple children and has conducted cancer screenings for 350,000 women, enhancing health services for key demographics [8] Group 5: Commitment to Health Improvement - Baoji's health authorities emphasize a commitment to improving public health services, focusing on accessibility and quality to support the overall well-being of its residents [9]

经观健康 术后冠脉造影，回旋支支架术后未见狭窄 姚道阔主任医师操作血管介入 手术控制系统与DSA联动，完成PCI手术 本次手术是北京友谊医院顺义院区成功完成的首例血管介入手术控制系统辅助经皮冠状动脉介入治疗手术。1月20 日，国产血管介入手术控制系统辅助完成经皮冠状动脉介入治疗手术的安全性和有效性全国多中心临床试验，首都 医科大学附属北京友谊医院分中心启动会顺利召开。标志着这一国家创新医疗器械正式在友谊医院西城院区、顺义 院区、通州院区三院区同步开展临床验证。宋现涛教授担任分中心主要研究者（PI），全面指导项目实施。手术的 顺利完成，彰显出医院在心血管介入诊疗领域的专业实力，以及对创新医疗技术的发展与应用。 血管介入手术控制系统介绍 2月4日，北京友谊医院顺义院区心内科顺利完成首例机器人（血管介入手术控制系统）辅助下经皮冠状动脉介入治 疗。该患者是一名65岁男性，因冠心病、不稳定型心绞痛入院，检查提示冠脉双支病变、回旋支重度狭窄，符合机 器人辅助手术指征。在北京友谊医院副院长、心血管中心主任宋现涛教授的支持与指导下，心内科主任医师姚道阔 团队精准操作，仅用时20分钟便顺利完成支架植入，手术圆满成功，患者恢复情 ...